Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metastasis Suppression and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD82 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD82 Large Extracellular Loop (LEL) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD82 Products |
| Gene Delivery | CD82 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for multi-pass membrane protein conformation preservation. |
View CD82 Products |
| Benchmark Ab | Anti-CD82 Recombinant Antibody Recombinant positive control for binding and flow cytometry assays. |
View CD82 Products |
| Validator | CD82 siRNA Set For knockdown verification and target specificity validation. |
View CD82 Products |
| Related Target A | CD9 Co-functional tetraspanin partner involved in cell adhesion and tumor progression. |
View CD9 Products |
| Related Target B | EGFR Epithelial growth factor receptor regulated by CD82-mediated internalization and signaling. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation of 4-Pass Membrane Protein | Lentivirus-driven stable cell line generation preserves native tetraspanin folding, avoiding unstable VLPs. |
| Tetraspanin Subfamily Cross-Reactivity | Recombinant Large Extracellular Loop (LEL) protein sequence verified to ensure specificity against CD9/CD81. |
| Lack of Controls | Recombinant Benchmark Antibodies and sequence-verified siRNA included for assay validation. |
| False Positives | High purity (>95%) and endotoxin-controlled (<1 EU/ug) proteins eliminate non-specific background noise. |
Live CD82 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD82 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination therapies and RNA-based restoration strategies. As first-generation therapies targeting the tumor microenvironment reach the clinic, the next wave of R&D is targeting CD82-mediated exosome signaling and stem cell niche maintenance in hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / ADC | Academic Institutes, Biotech Startups | Acute Myeloid Leukemia (AML), Solid Tumors | Cell-based binding & internalization assays (Lentivirus for stable cell lines) |
| mRNA / Gene Therapy | RNA Therapeutics Developers | Metastatic Prostate & Breast Cancer | Expression validation & functional migration assays (siRNA knockdown controls) |
| Exosome-Targeted Therapies | Exosome Biotech Specialists | Refractory Cancers, Diagnostics | High-purity LEL protein for exosome surface marker quantification |